Clinical Trials
8 trialsNCT04739566 2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2 Withdrawn
NCT02143050 2023-11-18
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
Phase 1/2 Withdrawn
NCT05299580 2023-09-14
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
Phase 2 Withdrawn
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT02447939 2018-09-14
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
GlaxoSmithKline
Phase 1 Withdrawn
NCT02672358 2018-08-10
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
Novartis
Phase 2 Withdrawn
NCT02915666 2018-05-15
A Clinical Trial of Patients With Melanoma
University of Texas Southwestern Medical Center
Phase 1 Withdrawn
NCT02357732 2015-12-11
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
University of Pittsburgh
Phase 1 Withdrawn